argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

819.14 27.13 −3.21%
Market cap
$53.2B
P/E
29.6×
Fwd P/E
32.4×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

29.27 39.97 30.23 33.47
P/S ratio
12.28 12.13 9.53 10.85
P/FCF ratio
0.00 87.59 77.00 41.94
P/Operating CF
0.00 0.00 0.00 0.00
P/B ratio
7.43 7.04 6.19 6.87
Price to Tangible BV
7.70 7.31 6.43 7.09
EV/Sales
11.71 11.31 8.80 10.18
EV/EBITDA
54.72 45.61 31.96 33.86
EV/Operating CF
(162.51) 57.23 49.81 33.57
EV/FCF
(96.14) 81.66 71.08 39.34
Quick Ratio
— 3.90 — 3.51
Current Ratio
— 5.23 — 5.12
Net Debt/EBITDA
0.00 (9.50) 0.00 (7.26)
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 — 0.00
Asset Turnover
0.00 0.64 0.00 0.72
Operating CF/Net income
0.00 0.00 0.00 0.00
Capex/Depreciation
— (3.97) — (0.47)
Interest Coverage
348.63 337.57 394.00 494.00
Research and Development Expense of Revenue
30.89% 27.78% 33.74% 31.52%
Selling, General and Administrative Expense of Revenue
29.21% 32.49% 27.04% 27.04%
Intangible Assets out of Total Assets
0.00 0.03 0.00 0.03
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Graham Net Nets
0.10 0.11 0.12 0.11
Graham Number
0.00 237.82 0.00 290.25
Earnings Yield
3.42% 2.50% 3.31% 2.99%
Free Cash Flow Yield
(0.99%) 1.14% 1.30% 2.38%
Revenue per Share
18.76 21.58 21.16 24.75
Operating CF per Share
0.00 0.00 0.00 0.00
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Cash per Share
0.00 56.95 0.00 57.52
Shareholders Equity per Share
0.00 119.47 0.00 135.08
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 119.47 0.00 135.08
Free Cash Flow
— 573.51 — 643.00
Working Capital
— 5,579.00 — 6,493.00
Capital Expenditures
— (111.68) — (8.00)
Net Current Asset Value
— 5,539.00 — 6,453.00
EV/EBIT
54.72 45.61 31.96 33.86
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
57.35 48.91 34.62 36.09
Other line items
Average Receivables
— 1,078.14 — 1,298.28
Average Payables
— 840.51 — 997.41
Average Inventory
— 392.28 — 348.73
Average Assets
0.00 6,612.73 0.00 7,414.28
Average Common Equity
— 5,710.25 — 6,339.62

Fold the line items

Columns are period end dates